These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27881277)

  • 1. Impact of Health Policy Changes on Trends in the Pharmaceutical Market in Turkey.
    Yılmaz ES; Koçkaya G; Yenilmez FB; Saylan M; Tatar M; Akbulat A; Gürsöz H; Kerman S
    Value Health Reg Issues; 2016 Sep; 10():48-52. PubMed ID: 27881277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region.
    Chen Y; Schweitzer SO
    Value Health; 2008 Mar; 11 Suppl 1():S124-9. PubMed ID: 18387056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses.
    Leopold C; Zhang F; Mantel-Teeuwisse AK; Vogler S; Valkova S; Ross-Degnan D; Wagner AK
    Int J Equity Health; 2014 Jul; 13():53. PubMed ID: 25062657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
    Maniadakis N; Kourlaba G; Shen J; Holtorf A
    BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.
    Moreno-Torres I; Puig-Junoy J; Raya JM
    Eur J Health Econ; 2011 Dec; 12(6):563-73. PubMed ID: 20809092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financing pharmaceuticals in transition economies.
    Kanavos P
    Croat Med J; 1999 Jun; 40(2):244-59. PubMed ID: 10234068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of factors affecting pharmaceutical expenditures.
    Mousnad MA; Shafie AA; Ibrahim MI
    Health Policy; 2014 Jun; 116(2-3):137-46. PubMed ID: 24726509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium.
    Fraeyman J; Van Hal G; De Loof H; Remmen R; De Meyer GR; Beutels P
    Acta Clin Belg; 2012; 67(3):160-71. PubMed ID: 22897063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment.
    Petrou P; Vandoros S
    Health Policy; 2015 May; 119(5):563-8. PubMed ID: 25837234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The new pharmaceutical policy in Italy.
    Fattore G; Jommi C
    Health Policy; 1998 Oct; 46(1):21-41. PubMed ID: 10187653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Turkey. Health system review.
    Tatar M; Mollahaliloğlu S; Sahin B; Aydin S; Maresso A; Hernández-Quevedo C
    Health Syst Transit; 2011; 13(6):1-186, xiii-xiv. PubMed ID: 22455830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of Cost Containment and Price Policies on Pharmaceutical Expenditure in South Korea.
    Kim W; Koo H; Lee HJ; Han E
    Int J Health Policy Manag; 2022 Oct; 11(10):2198-2207. PubMed ID: 34814666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Policy in Latvia.
    Silins J; Szkultecka-Dębek M
    Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
    Inotai A; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
    [No Abstract]   [Full Text] [Related]  

  • 20. The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study.
    Armeni P; Jommi C; Otto M
    Eur J Health Econ; 2016 Nov; 17(8):963-977. PubMed ID: 26507643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.